Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 11, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Lung cancer in developing countries: access to molecular testing.

Carlos Gil Ferreira1

  • 1From the Brazilian National Cancer Institute, Rio de Janeiro, Brazil.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 30, 2013
PubMed
Summary

Personalized medicine for non-small cell lung cancer requires molecular testing. Developing countries face challenges in providing access to these crucial diagnostic tools for lung cancer patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PD-L1 score among non-small cell lung cancer patients: are we holding out for a hero?

Journal of thoracic disease·2026
Same author

Sotorasib in Advanced <i>KRAS</i> G12C-Mutated NSCLC: Results From the Global Expanded Access Program, Including Patients With Poor Performance Status and a History of CNS Metastases.

JTO clinical and research reports·2026
Same author

Increased detection of NRG1 fusions in non-squamous non-small cell lung cancer using combined DNA and RNA sequencing in a real-world cohort.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Modulation of Patient-Derived Tumor Organoids by SARS-CoV-2 Variants Across Cancer Types: A Study Combining Morphology, Inflammation, and Whole-Exome Profiling.

International journal of molecular sciences·2026
Same author

ROS1 therapy among patients with advanced non-small cell lung cancer: an endless road to rediscover?

Chinese clinical oncology·2025
Same author

Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary.

Future oncology (London, England)·2025

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Global Health

Background:

  • Personalized medicine is transforming non-small cell lung cancer (NSCLC) treatment, particularly for adenocarcinoma.
  • Molecular testing is now integral to clinical decisions in developed healthcare systems.
  • Significant disparities exist in access to these essential diagnostic tests in developing nations.

Purpose of the Study:

  • To highlight the critical need for improved access to molecular testing for lung cancer patients in developing countries.
  • To emphasize the necessity for healthcare systems in developing nations to adapt and integrate molecular diagnostics.
  • To outline key considerations for implementing personalized medicine strategies in resource-limited settings.

Main Methods:

  • This study is a review and analysis of current challenges and potential strategies for molecular testing access in developing countries.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Experiment Videos

Last Updated: May 11, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

  • It synthesizes information on the importance of molecular epidemiology, quality control, and professional education.
  • The analysis considers regulatory pathways for drugs and companion diagnostics.

    • Main Results:

    • Access to molecular testing for lung cancer is severely limited in developing countries.
    • Tailored strategies are essential due to diverse national contexts.
    • Key requirements include local data generation, quality assurance, and professional training.

    Conclusions:

    • Developing countries must adapt healthcare systems to provide equitable access to molecular diagnostics for lung cancer.
    • Addressing challenges in local epidemiology, quality control, education, and regulatory frameworks is crucial.
    • Implementing innovative, context-specific strategies is necessary to advance personalized lung cancer care globally.